Frenkel Ran 4
4 · Karyopharm Therapeutics Inc. · Filed Mar 2, 2022
Insider Transaction Report
Form 4
Frenkel Ran
EVP, WW Development Operations
Transactions
- Award
Common Stock
2022-02-28+68,250→ 169,953 total - Sale
Common Stock
2022-02-28$10.24/sh−1,663$17,025→ 168,290 total - Award
Stock Option (right to buy)
2022-02-28+90,000→ 90,000 totalExercise: $10.33Exp: 2032-02-27→ Common Stock (90,000 underlying)
Footnotes (4)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.
- [F2]This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
- [F3]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.41, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.